Non-invasive ventilation in the treatment of sleep-related breathing disorders: A review and update

A. Nicolini, P. Banfi, B. Grecchi, A. Lax, S. Walterspacher, C. Barlascini, D. Robert

Abstract Non-invasive mechanical ventilation (NIV) was originally used in patients with acute respiratory compromises or exacerbations of chronic respiratory diseases as an alternative to intubation. Over the last thirty years NIV has been used during the night in patients with stable chronic lung diseases such as obstructive sleep apnea, the overlap syndrome (COPD and obstructive sleep apnea), neuromuscular disorders, obesity-hypoventilation syndrome and in other conditions such as sleep disorders associated with congestive heart failure.

In this review we discuss the different types of NIV, the specific conditions in which they can be used as well as the indications, recommendations, and evidence supporting the efficacy of NIV.

© 2013 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. All rights reserved.
Background

Noninvasive mechanical ventilation (NIV) is any form of ventilatory support without an endotracheal tube. NIV was originally used in patients with acute respiratory compromises or exacerbations of chronic respiratory diseases, as an alternative to the endotracheal tube. Over the last thirty years NIV has been also used during the night in patients with stable chronic lung disease such as obstructive sleep apnea (OSA), chronic obstructive pulmonary disease (COPD), the overlap syndrome (COPD and obstructive sleep apnea), neuromuscular disorders, obesity-hypoventilation syndrome (OHS), and sleep disorders associated with congestive heart failure (Cheyne-Stokes respiration). In this review we discuss the different types of NIV, the specific conditions in which they can be used as well as the indications, recommendations and evidence supporting the efficacy of NIV.

Clinical conditions for NIV

Alveolar hypoventilation is a result of an imbalance between the capability of respiratory muscles to maintain ventilation and gas exchange and is characterized by hypercapnia assessed by blood gas analysis. If pathologies related to either peripheral and/or central nervous system dysfunction are excluded, the other conditions associated with developing alveolar hypoventilation are listed in Table 1. Of note, alveolar hypoventilation primarily develops during sleep; moreover, in all these entities daytime breathing abnormalities must be considered. These respiratory “daylight” deteriorations (particularly in patients with neuromuscular disorders) require an appreciation of the diagnosis, the progression of the disease, and the particular circumstances of the patient.

Obstructive sleep apnea–hypoapnea syndrome (OSA)

OSA has an incidence of 2% in women and 4% in men. It is characterized by recurrent episodes of partial (hypopnea) or complete (apnea), obstruction of the upper airway during sleep, and is associated with episodes of arousal and/or oxyhemoglobin desaturation. Symptoms of the syndrome include excessive daytime sleepiness, choking episodes during sleep, frequent awakenings, unrefreshing and unstructured sleep, daytime fatigue, difficulty concentrating and short-term memory loss (Table 2). The pathophysiology of OSA remains controversial. Obesity, the classic hallmark in OSA, is associated with obstruction of the
muscles of the pharynx must produce a greater contraction to overcome the tendency of the pharyngeal wall to collapse (due to the negative pressure inside the cavity and pharynx). The supine position is potentially dangerous in some circumstances because the tongue tends to occlude the rear wall of the oropharynx which can increase the oropharynx occlusion. This syndrome has been associated with the development of hypertension, coronary artery disease, bleeding disorders, stroke, and increased risk of sudden death during sleep. It is also associated with a higher rate and greater severity of traffic accidents, increased use of health care facilities and reduced capacity for work. Evidence exists that non-invasive ventilation, usually continuous airway positive pressure (CPAP), has significant advantages in this type of disease, improving sleep quality, daytime wakefulness, and cognitive function and so the quality of life improves. These improvements are wide-ranging: reduction of traffic accidents, lower arterial blood pressure and reduction in the morbidity and mortality rates of myocardial infarction and stroke demonstrate the wide spectrum of CPAP's benefits.

Complex sleep apnea

We use the term ‘‘Complex Sleep Apnea’’ (CompSAS) to indicate a condition initially diagnosed as OSA. This syndrome is characterized (while CPAP is being used) by the frequent occurrence of central apnea after elimination of obstructive events. CompSAS is diagnosed based on minimal apnea–hypoapnea index (AHI) of five events per hour of sleep with a majority of obstructive events. If during titration there is a reduction in the number of obstructive events to <5 events per hour of sleep, while the central apnea index (CAI) is >5 events per hour sleep, the diagnosis is established. Rather than starting further treatments it is useful to consider whether CPAP pressure is too high and is provoking CompSAS (pressure toxicity). Patients with CompSAS most often respond to positive airway pressure, but the obstruction cannot be eliminated without producing central apnea. A possible preventive measure is the so-called permissive flow-limitation: the pressure is set at a level that permits a mild degree of airway obstruction, without disturbing ventilator control mechanisms. Also oxygen administration may lead to a decrease in the hypoxic ventilatory response. Also BiPAP in the spontaneous-timed (ST) mode or adaptive servo-ventilation (ASV) can be useful in the treatment of CompSAS.

Sleep-disturbances associated with cardiac dysfunction

The prevalence of obstructive sleep apnea in patients with impaired left ventricular ejection fraction is estimated to be about 11–53%. It is also known that the sleep obstructive apnea–hypoapnea syndrome can worsen a state of congestive heart failure, by causing a periodic increase in negative intrathoracic pressure, by raising arterial blood pressure, and causing tachycardia from sympathetic nervous system stimulation from hypoxia, hypercapnia and arousals. CPAP treatment produces a reduction in blood pressure and improves left ventricular systolic function in patients with chronic heart failure and obstructive sleep apnea. Recent studies in patients with chronic heart failure associated with obstructive sleep apnea have shown a further improvement in cardiac function in patients treated with bilevel positive airway pressure ventilation (BIPAP). This may be due to the lower respiratory muscle work due to BIPAP. Moreover, reduced work of breathing, a lower positive intrathoracic pressure gives a greater ejection fraction. Central sleep apnea (CSA) is associated with periodic breathing. Periodic breathing, Cheyne-Stokes respiration, is a particular variety of central sleep apnea which is frequently associated with congestive heart failure. CSA with its characteristic desaturation (apnea-related) and sympathetic hyperactivity tends to worsen the prognosis of heart failure. CSA is characterized by cessation of respiratory drive during sleep, which causes impaired gas exchange. Unlike the OSA in which there is a respiratory effort to overcome the resistance of the upper airway, CSA is characterized by the absence of respiratory movement due to the cessation of ventilation. In the heart failure patients, the onset of apnea occurs through a redistribution of blood volume from the lower limbs to pulmonary circulation that is primarily triggered by the supine position. Stimulation of pulmonary vagal receptors causes hyperventilation which results in hypcapnia. When the value decreases below the hypocapnic apnoeic threshold, stimulation of the bulbar center ceases, inspiratory drive stops, and apnea occurs. In patients with chronic heart failure, the prolonged circulation time due to the reduction in cardiac output leads to a delay of feedback between chemoreceptors and bulbar centers resulting in hyperventilation and respiratory instability. The main risk factors for CSA are male sex, hypocapnia, atrial fibrillation and advanced age. CPAP and BIPAP are often unable to correct this category of apneas; therefore, a servo-assisted mode (ASV or adaptive servo ventilation) is recommended.

The ASV device determinate automatically the extent of ventilatory support based on a continuous analysis of the breathing pattern and in more advanced machines also the expiratory pressure adjustment. Some studies have shown it to be most effective in controlling this type of apnea; it remains unclear whether ASV increases survival in these patients.

Obesity-hypoventilation syndrome

Obesity hypoventilation refers to a syndrome including daytime hypercapnia (PCO2 > 45 mmHg) in obese people in which no other cause of hypoventilation is present. Its prevalence among patients with obstructive sleep apnea is 20–30% and is greater in extremely obese patients (BMI > 40). Approximately 10% of patients with obesity-hypoventilation syndrome do not have obstructive sleep apnea syndrome. Additionally, nocturnal hypoxemia and diurnal hypercapnia persist in about 40% of these patients after the treatment when CPAP eliminated apnea. Other factors contribute to the development of obesity-hypoventilation syndrome associated with the persistence of daytime hypercapnia: these include body mass index and apnea–hypoapnea index, mean overnight oxygen saturation, and the severity of restrictive ventilatory syndrome. CPAP treatment is most
effective when there are certain predictive values: better spirometry results, and a higher apnea–hypoapnea index. BIPAP therapy may be useful in those patients for whom CPAP has failed or given unsatisfactory results. Titration of non-invasive ventilation pressure should follow the recommendations of pressure titration in obstructive sleep apnea with the goal of eliminating (hypo)apneas, snoring, respiratory effort-related arousals and lowering pCO\textsubscript{2} levels to at least daytime values.\textsuperscript{25,26} No recommendations exist regarding the ventilation mode to favor in OHS.\textsuperscript{39} Trials exist providing evidence that a high backup respiratory rate leads to superior night-time control of respiratory events.\textsuperscript{40,41}

The average volume-assured pressure support ventilation seems to be able to lower pCO\textsubscript{2}, but data regarding effect on oxygenation and long-term outcome are conflicting.\textsuperscript{42–45}

Neuromuscular and chest wall disorders

NIV has been used in patients with progressive neuromuscular disease or serious abnormalities of the thoracic cage, with recognized benefits, which include an improved survival rate and an improved quality of life. The benefits of NIV in this type of patient includes improvements of daytime levels of blood gas (including hypercapnia), a reduction in the oxygen cost of breathing, an increase in the ventilatory response to increased carbon dioxide, and improved lung compliance.\textsuperscript{46}

Chronic obstructive pulmonary disease and sleep apnea (overlap syndrome)

COPD is a challenging and ever increasing chronic pulmonary disease, affecting health care systems worldwide. It is projected to be fourth leading cause of mortality by 2030. COPD severely impacts quality of life.\textsuperscript{47} In severe COPD acute exacerbations often lead to acute hypoxemic and/or hypercapnic respiratory failure, resulting in further disease progression and possible chronic respiratory failure.\textsuperscript{48}

NIV is considered first-line treatment in acute exacerbations of COPD requiring ventilatory support,\textsuperscript{49} but recommendations regarding establishment of domiciliary long-term non-invasive ventilation in chronic hypercapnic failure due to COPD are conflicting.\textsuperscript{50} Sleep-disordered breathing (mainly obstructive sleep apnea) and chronic obstructive pulmonary disease (COPD) are the most common lung diseases: a large number of patients have both disorders, hence the term “overlap syndrome.”\textsuperscript{51,52}

The COPD overlap syndrome was first described by Flenley in 1985 as a combination of COPD and obstructive apnea–hypoapnea syndrome.\textsuperscript{53} Epidemiological studies have not shown a consistently higher incidence of sleep apnea–hypoapnea syndrome in patients with COPD compared to common OSA.\textsuperscript{54} Nevertheless, the coexistence of these conditions can lead to severe episodes of desaturation during sleep (particularly during rapid eye movement – REM-sleep),\textsuperscript{54} thus increasing the risk of hypoxemia, daytime hypercapnia and pulmonary hypertension.\textsuperscript{55} This results in a substantially greater morbidity and mortality, compared to those with COPD or OSA alone as well as more hospitalizations and higher mortality. Many questions remain about the definition of the disease, the prognosis and the optimal treatment which currently consists of CPAP and oxygen. Non-invasive ventilation may be useful in patients with overlap syndrome, but there are no controlled studies.\textsuperscript{56,57}

Clinical criteria for starting non-invasive ventilation

The presence of symptoms and physiological markers of hypoventilation are useful in identifying the clinical severity; moreover, these factors relate to therapeutic decision-making, especially initiating nocturnal non-invasive ventilation.\textsuperscript{1,2} In a typical “progressive disease” two consecutive steps occur:

1. Initial phase of nocturnal hypoventilation reversible during waking hours, associated with few or no clinical symptoms.

2. Nocturnal and daylight hypoventilation associated with clinical symptoms (see Table 3) which shows a reduced respiratory reserve.

Continuous sleep monitoring of pCO\textsubscript{2} and O\textsubscript{2} saturation values is necessary to document the presence of nocturnal hypoventilation which may be present in all the stages of sleep (in some cases only during REM sleep). Daytime hypoventilation is defined by reduced values of arterial oxygen tension (PaO\textsubscript{2} <55 mmHg), high levels of arterial carbon dioxide tension (PaCO\textsubscript{2} 45–50 mmHg) and/or high serum bicarbonate levels with a relatively normal pH. Chronic daytime hypoventilation is an important indicator always associated with nocturnal hypoventilation (PaCO\textsubscript{2} ≥55 mmHg or a rise in PtcCO\textsubscript{2} to ≥10 mmHg).\textsuperscript{52} In the presence of daytime hypoventilation, polysomnography is recommended to exclude sleep apnea.\textsuperscript{5} Clinical symptoms, although modest, should be evaluated carefully, because they are very important determining disease severity and prognosis as well defining the need for NIV. Pulmonary function tests may be helpful in defining the reduction of lung function, but they have a low predictive value for patients with sleep-related hypoventilation.\textsuperscript{2,52} However, in patients with neuromuscular disease, there is a good correlation between lung function and nocturnal hypoventilation: it has

### Table 3 Clinical features frequently associated with alveolar hypoventilation.\textsuperscript{1,2}

<table>
<thead>
<tr>
<th>Condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shortness of breath during activities of daily in the absence of paralysis</td>
</tr>
<tr>
<td>Orthopnea in patients with disordered diaphragmatic dysfunction</td>
</tr>
<tr>
<td>Poor sleep quality: insomnia, nightmares and frequent arousals</td>
</tr>
<tr>
<td>Nocturnal or early morning headaches</td>
</tr>
<tr>
<td>Daytime fatigue, drowsiness, loss of energy</td>
</tr>
<tr>
<td>Decrease in intellectual performance</td>
</tr>
<tr>
<td>Appearance of recurrent complications: respiratory infections</td>
</tr>
<tr>
<td>Clinical signs of cor pulmonale</td>
</tr>
</tbody>
</table>
been shown that hypoventilation during REM only or during all sleep stages or in the daytime, appears respectively with supine inspiratory vital capacities of less than 40%, 25% or 12% of predicted values.  

Types of NIV and their use

We now consider the main types of ventilation used to treat sleep-disordered breathing and respiratory conditions associated with hypoventilation and hypercapnia.

CPAP (continuous positive airway pressure)

CPAP is currently the most widely used mode of NIV in the treatment of obstructive sleep-disordered breathing and acute hypoxemic failure associated with chronic heart failure. It consists in the application of a constant level of positive pressure during spontaneous breathing. However, it has to be noted that CPAP should be only applied in sufficiently spontaneous breathing patients. It is not considered as a mode of mechanical ventilation. The mechanism of action of CPAP includes a series of actions on pathophysiological mechanisms:

(a) It prevents intermittent narrowing and collapse of the airways in patients with obstructive sleep apnea–hypopnea syndrome (by acting a virtual splint during sleep).
(b) It counteracts auto-positive end-expiratory pressure, which reduces respiratory muscles load, the work of breathing and daytime PaCO$_2$ in patients with overlap syndrome.
(c) It improves lung function, particularly the functional residual capacity, daytime gas exchange in patients with obstructive sleep apnea–hypopnea syndrome.
(d) It improves systolic function of the left ventricle in patients with heart failure coexisting with obstructive sleep apnea–hypopnea syndrome.

Auto-CPAP (automatic adjustment of continuous positive airway pressure)

Auto-CPAP (APAP) is delivered via a self-titrating CPAP device, which uses algorithms to detect variations in the degree of obstruction and adjusts the pressure level to restore normal breathing. Auto-CPAP compensates for factors that modify the upper airway collapsibility, such as body position during sleep, stage of sleep, use of alcohol, and drugs that affect upper airway muscle tone. The auto-CPAP can be used during polysomnography or cardiorespiratory monitoring to titrate a single pressure value to be used later with fixed CPAP for treatment of OSA in patients without comorbid conditions (chronic heart failure, COPD, central apnea syndrome or hypoventilation). The use of auto-CPAP is reserved only for those patients with sleep apnea syndrome only present during REM or respiratory events related to position, in whom constraining positional maneuvers are poorly tolerated.

Adaptive servo-ventilation (ASV)

The adaptive servo-ventilation (ASV) has been developed for the treatment of Cheyne-Stokes respiration-central apnea syndrome in patients with chronic heart failure who have a breathing pattern characterized by periods of crescendo–decrescendo change in tidal volume. This complex device can use patient expiratory positive airway pressure (EPAP) level sufficient to control the obstructive apnea. The device then automatically adjusts the inspiratory pressure support for each inspiration within a pre-specified range, to maintain a moving-target ventilation set at 90% of the patient’s recent average ventilation. The aim is the stabilization of breathing patterns and to reduce the respiratory alkalosis which can trigger apnea re-entry cycles.

BIPAP (bilevel positive airway pressure)

Bilevel positive airway pressure (BIPAP) is also used for sleep-related disorders, but its main indication is in pathological conditions associated with hypoventilation. The BIPAP devices deliver a higher pressure during inspiration (IPAP – inspiratory positive airway pressure) and a lower pressure during expiration (EPAP – expiratory positive airway pressure). The gradient between IPAP and EPAP (pressure support ventilation) is crucial in maintaining adequate alveolar ventilation and reducing PaCO$_2$. The IPAP acts also in reducing the work of breathing and fatigue, reducing the workload of respiratory muscles; EPAP has the function of maintaining the patency of the upper airway, to control obstructive apnea and to improve the functional residual capacity. BIPAP is now proposed for the type of patients who require high expiratory pressures to control obstructive sleep apnea–hypopnea, but who cannot tolerate exhaling against a high-fixed CPAP pressure. Other indications of BIPAP are the treatment of coexisting central apnea or hypoventilation, the obesity-hypoventilation syndrome, the overlap syndrome and neuromuscular disorders. Although the patient should be able to maintain spontaneous breathing, it is used to set a back-up rate option for those patients whose ventilation during sleep may be particularly impaired (neuromuscular disorders, complex sleep apnea, central apnea in chronic heart failure, obesity-hypoventilation syndrome). Recently a new device has been introduced: an auto-adjusting bi-level positive airway pressure (auto-BIPAP) to provide greater flexibility in pressure changes for bi-level therapy. This treatment results in AHI (apnea–hypopnea index) reduction equivalent to that provided by a conventional BIPAP.

Average volume-assured pressure support ventilation (AVAPS)

Average volume-assured pressure support ventilation (AVAPS) is used in patients with chronic hypoventilation and in particular with obesity hypoventilation syndrome, neuromuscular diseases, and sometimes, in chronic obstructive pulmonary disease. In this mode a target tidal volume is set; the device adjusts the pressure support which to reach the selected tidal volume. It guarantees a delivered tidal...
volume adjusted despite variability in the patient effort, airway resistance, and lung or chest wall compliance. A particular benefit of this mode is that it may be modified as the disease progresses (as it occurs in neuromuscular disorders such as amyotrophic lateral sclerosis). Yet, this system remains controversial. It is not known if and to what extent hybrid ventilation modes (i.e. pressure-targeted ventilation with assured volume support) are beneficial in the management of chronic hypercapnic failure. Further large-scaled studies are needed.

The various types of non-invasive positive pressure ventilation and their indications for the non-invasive ventilation for the various disorders are shown in Tables 4 and 5.

### Application and management of NIV

#### Nocturnal CPAP titration

The titration of the therapeutic value of CPAP (value of positive pressure necessary to eliminate the sleep apnea) can be made with one of the following methods:

1. Sleep study with complete laboratory staff dedicated to monitoring and manual CPAP titration performed during polysomnography (the pressure is gradually increased to normalize the breathing pattern during sleep).
Table 5  Non-invasive ventilation indication.3,49,50,59

Chronic obstructive pulmonary disease (COPD)

NIV without backup rate

PaCO₂ ≥ 50 mmHg when the patient is awake and O₂ saturation ≤ 88% (≥ 2 h of recording on nocturnal oximetry) while on the higher of 2 L per minute of O₂ and obstructive sleep apnea and CPAP treatment have been considered and ruled out by facility-based nocturnal polysomnography.

NIV with backup rate, anytime after use without backup rate

PaCO₂ ≥ 7 mmHg greater than the original qualifying result and O₂ saturation ≤ 88% for ≥ 5 min (2 h of recording on facility-based nocturnal polysomnography) while on NIV without backup rate and apnea–hypopnea index < 5

Restrictive thoracic disorders: progressive neuromuscular disease or thoracic cage abnormalities

NIV with or without backup rate

PaCO₂ ≥ 45 mmHg or O₂ saturation ≤ 88% for ≥ 5 minutes (≥ 2 h of recording on nocturnal oximetry) or (for neuromuscular diseases only) maximal inspiratory pressure (MIP) ≤ 60 cm H₂O or FVC ≤ 50% of predicted

Central sleep apnea or complex sleep apnea syndrome

NIV with or without backup rate

All the following on facility-based on nocturnal polysomnography: apnea–hypopnea index > 5, central events > 50% of total, central events ≥ 5 per hour, excessive daytime sleepiness or disrupted sleep and significant improvement on NIV and FiO₂

Obstructive sleep apnea

Continuous positive airway pressure (CPAP)

Apnea–hypopnea syndrome index/respiratory disturbance index ≥ 15 (minimum 30 events) or apnea–hypopnea index/inspiratory disturbance index 5–14 with symptoms or cardiovascular risks (excessive daytime sleepiness, impaired cognition, mood disorders, insomnia, hypertension, ischemic heart disease, history of stroke)

NIV without backup rate

Above criteria and CPAP ineffective on polysomnography or at home cardio-respiratory monitoring

Hypoventilation syndrome

NIV without backup rate

Awake PaCO₂ ≥ 45 mmHg and PaCO₂ ≥ 7 mmHg greater during sleep or upon awakening or O₂ saturation ≤ 88% for ≥ 5 min (≥ 2 h of recording on facility-based nocturnal polysomnography) with an apnea–hypopnea index < 5

NIV with backup rate

Awake PaCO₂ up ≥ 7 mmHg from initial qualifying PaCO₂ despite using NIV without backup rate or O₂ saturation ≤ 88% for ≥ 5 min (≥ 2 h of recording on facility-based nocturnal polysomnography) while on NIV without backup and apnea–hypopnea index < 5

(2) Complete polysomnographic study (with or without the continued presence of dedicated staff) with titration performed with auto-CPAP (usually the value of the 90th percentile).

(3) Polysomnographic full study or complete cardiorespiratory monitoring performed during nocturnal CPAP therapy whose value has been obtained on the basis of data extracted from the device auto-CPAP in the previous nocturnal recording (usually the value of the 90th percentile).

(4) Sleep study with complete laboratory staff dedicated to monitoring and titration of CPAP polysomnography performed in the course of using the split-night in which the patient is evaluated for 50% of the night in spontaneously breathing and the other 50% in incremental CPAP.1,69,70

Titration of PAP obtained by auto-CPAP therapy should be derived from visual analysis of a large recording period free of artifacts. The optimum pressure value of CPAP is the value which eliminates (in the course of a complete polysomnographic investigation) each apnea, hypoapnea, arterial desaturation, snoring, respiratory effort-related arousal (RERA) in each stage of sleep and body position. The same applies in the course of a complete cardiorespiratory monitoring.1,2 An acceptable level of CPAP leads to a low number of events residues during the titration procedures. The final value of pressure (PAP) is always a compromise between the function of patient adherence, the absolute value of PAP reached, and the clinical benefits derived.

It is also recommended that the procedures for titration of CPAP in points 2, 3 and 4 are made exclusively in patients with OSA in the absence of comorbidities such as COPD, chronic heart failure, and neuromuscular disorders.1,69–71

Management of non-invasive ventilation

Initiation and settings in case of nocturnal ventilation

The main objective of NIV use is the correction of blood gas values to near “normal” with the least possible discomfort or sleep disturbance. It is good practice to proceed in three successive steps.1 The first step is to choose and adjust the ventilator settings while the patient is awake,
assuring physiological adequacy and patient comfort for at least 1 or 2 h. In the second step the clinician should evaluate the adequacy of the settings when sleeping during a nap and a night’s sleep. Different options, according to the resources available in each center, are used. A full polysomnography recording oxygen saturation (SpO\(_2\)) and trans-cutaneous pCO\(_2\) (PtcCO\(_2\)) or end-tidal (PetCO\(_2\)), flow, tidal volume, airway pressure, rib cage and abdomen excursion and sleep-staging allows a complete assessment.\(^1,2,52\)

When the resources are not available fewer parameters may be used. The minimum required is recording SpO\(_2\) on room air, assessing that the normalization of SpO\(_2\) accompanies the normalization, or at least the improvement in PaCO\(_2\).

The second step relates to patient tolerance, comfort, changes in sleep quality and well-being; these data should be obtained. The third step consists of looking for reduction in PaCO\(_2\) and augmentation of PaO\(_2\) without dyspnea during the day in free ventilation after several nights of NIV. This is done to confirm that the settings are adequate for the patient’s needs.\(^1,71\)

The main purpose for the application of NIV is the correction of hypercapnia to physiological levels.\(^5,6\) Lately, a technique called “high-intensity NIV” has emerged, applying inspiratory pressure levels up to 28 cm H\(_2\)O and high back-up respiratory rates in order to achieve pCO\(_2\) control in stable hypercapnic COPD patients.\(^2,7\) This approach has been physiologically proven to reduce inspiratory effort, when compared to conventional ventilation strategies.\(^2\) Furthermore, high-intensity NIV does not negatively influence sleep quality,\(^5\) and improves blood gases, lung function, hematocrit, and decrease COPD exacerbations rates.\(^5\) However, it remains controversial what impact the setting of the breathing frequency has on ventilation quality in COPD.\(^7,6\)

If the results are not satisfactory, changes must be made to the settings. One may also change the type of mask and ventilator. At the beginning a starting level of pressure support of 10 cm H\(_2\)O is recommended. Continuing the adaptation, the pressure level can progressively be increased to achieve evidence of improvement. Pressure support higher than 20 cm H\(_2\)O is rarely necessary.\(^1\) A back-up frequency set close to the spontaneous frequency of the patient during sleep is a reasonable step.\(^1,3\)

When employing a volume-preset ventilator, the initial suggested setting may be established by adjusting the frequency of ventilator-delivered breaths so that it approximates the patient’s spontaneous breathing frequency during sleep, an inspiratory time/total breathing time between 0.33 and 0.5 and a relatively high tidal volume of around 10–15 ml/kg to insure sufficient tidal volume in case of leaks.\(^1,3\)

Supplemental oxygen (O\(_2\)) will be added to the ventilator circuit, especially in those patients who require oxygen during the daytime (COPD, cystic fibrosis, bronchiectasis). However, oxygen delivery varies greatly with the tubing system used (active valve port, leak port circuit). Furthermore, optimal mask fitting must be titrated in a clinical setting.\(^1,7\) In the absence of obstructive pulmonary disease, the addition of O\(_2\) to the ventilation circuit may be justified only to maintain an acceptable level of PaO\(_2\) during sleep and only after all the parameters have been optimized.\(^78\)

The choice of the mask

The interface is of paramount importance for adherence to NIV therapy. The choice of this device should be done with special care to meet patient’s needs. Considering the type of treatment planned and favoring masks which deliver positive pressure through both the nose and the mouth (if the patient is a mouth breather) is of great importance.\(^29\)

Every effort should be made to minimize air leaks, maximize patient comfort and optimize patient-ventilator interaction.\(^40\) Technological issue to consider when choosing the NIV interface include the site and type of exhalation port, and how the ventilator algorithm functions with different masks. Heating and humidification may be needed to prevent adverse effects from cool dry gas.\(^80,81\)

Continuous NIV

In patients with neuromuscular disorders (to a lesser degree in end-stage stage lung disease), ventilatory dependency can be total at the starting of non-invasive ventilation or may gradually increase following the progressive worsening of the disease. In case of continuous need for assisted ventilation, non-invasive ventilation may be started and maintained with modifications of the mode of ventilation (e.g. changing ventilation mode between day and night and/or alternating various interface types: nasal, oral, oronasal, mouth-piece) and associated, where possible, with assisted coughing.\(^1,82\)

Follow-up

Clinical follow-up and daytime arterial blood gases should be performed at least twice a year.\(^1,2\) The recordings during sleep (possibly identical to those performed for the adaptation to non-invasive ventilation), are useful. At any time, when there are indications of unsatisfactory results such as the recurrence of clinical symptoms and/or signs of hypoventilation on arterial blood gases, inadequate non-invasive ventilation should be suspected, and a complete objective assessment of ventilation during sleep with polysomnography must be undertaken.

When the NIV is not proven to be optimal, a change of ventilation modality and/or parameters of the ventilator and/or a revision of the interface may be indicated. In case of disease progression one should be considered increasing the duration of ventilation during the day. The interfaces need to be regularly checked and modified or adapted to changing needs of the patient.\(^1,69,71\)

Management of complications

Air leaks during ventilation

The major potential adverse effect is the loss of effectiveness of the ventilation and therefore the potential fragmentation of sleep. A variety of more or less effective measures have been suggested to tackle the problem of leaks during NIV. These include the prevention of neck flexion, the semi-recumbent positioning of the patient, the use of a chin rest or a cervical collar to prevent opening of the
Humidification of delivered gas may improve these symptoms. Sleep specialists should review the results of objective testing with the patient. Education of the patient is mandatory.

The choice of ventilator, its setting, the choice of interface between patient and ventilator are crucial for the success of NIV. A variety of masks are now available and manufacturers continue to improve mask design. Oro-nasal mask should be considered if the patient is mouth breather to avoid leaks through open mouth. In the past there were ventilators which had only pressure or volume controlled modes. Today most ventilators can work in either mode and the choice of the equipment should be considered by the patient’s point of view. The patient’s point of view is clinically relevant because better patient well-being is related to a better treatment adherence. This is a critical issue especially in patients chronically treated with non-invasive ventilation.

**Ethical disclosures**

**Protection of human and animal subjects.** The authors declare that no experiments were performed on humans or animals for this study.

**Confidentiality of data.** The authors declare that no patient data appear in this article.

**Right to privacy and informed consent.** The authors declare that no patient data appear in this article.

**Conflicts of interest**

The authors have no conflicts of interest to declare.

**References**


60. Mc Murray JJ, Adamopoulos S, Anker SD, Aurielacho A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803–69.


